V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214135 | 20080470 | 1.8 | 63 | null | 2019-08-31 | 2019-09-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101531698 |
| 20214136 | 20080471 | 0 | 76 | Palliative (P) | 2018-09-09 | 2018-09-09 | GO2 TRIAL | 01 | N | TRIAL | 100047833 |
| 20214138 | 20080473 | 1.63 | 86 | Curative (C) | 2019-09-13 | 2019-10-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101482805 |
| 20214139 | 20080474 | 1.73 | 58 | Palliative (P) | 2016-07-14 | 2016-07-26 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100879164 |
| 20214140 | 20080475 | null | 92.5 | Curative (C) | 2016-04-27 | 2016-05-15 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100828958 |
| 20214141 | 20080476 | 1.75 | 97 | Palliative (P) | 2018-03-11 | 2018-03-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100919473 |
| 20214142 | 20080477 | 1.77 | 88.7 | Palliative (P) | 2019-08-11 | 2019-08-14 | Trial Unspecified | Y | N | TRIAL | 100835981 |
| 20214143 | 20080478 | 1.85 | 84.8 | Palliative (P) | 2018-03-27 | 2018-04-13 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101143328 |
| 20214144 | 20080479 | 1.82 | 59 | Palliative (P) | null | 2018-01-21 | null | null | N | TRIAL | 101546655 |
| 20214145 | 20080480 | 1.65 | 106 | Palliative (P) | 2019-05-02 | 2019-05-09 | Trial Unspecified | Y | N | TRIAL | 100027339 |
| 20214147 | 20080481 | 1.6 | 81.2 | Palliative (P) | 2016-06-04 | 2016-06-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101784137 |
| 20214149 | 20080483 | 1.6 | 78 | Palliative (P) | 2018-08-05 | 2018-08-12 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101641037 |
| 20214150 | 20080484 | null | 70 | Palliative (P) | 2019-11-15 | 2019-11-16 | LANREOTIDE | 02 | N | LANREOTIDE | 101196865 |
| 20214151 | 20080485 | 1.58 | 0 | null | 2018-03-05 | 2018-03-15 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 101252201 |
| 20214152 | 20080486 | 1.7 | 63 | Curative (C) | 2018-05-23 | 2018-06-19 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100795067 |
| 20214153 | 20080487 | 1.6 | 52.4 | Curative (C) | 2017-05-28 | 2017-06-02 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101302666 |
| 20214154 | 20080488 | 1.78 | 63.2 | Palliative (P) | 2018-02-03 | 2018-02-19 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100412874 |
| 20214155 | 20080489 | 1.69 | 76.7 | null | 2018-03-29 | 2018-04-16 | LANREOTIDE | 02 | null | LANREOTIDE | 100649269 |
| 20214157 | 20080490 | 1.71 | 77 | Palliative (P) | 2017-04-12 | 2017-05-05 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101583314 |
| 20214158 | 20080491 | 1.71 | null | Palliative (P) | 2020-02-07 | 2020-02-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 99 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100448634 |
| 20214159 | 20080492 | 1.8 | 71 | Palliative (P) | 2019-05-26 | 2019-06-15 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100434790 |
| 20214160 | 20080493 | 1.75 | null | Palliative (P) | 2018-01-31 | 2018-02-21 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101779126 |
| 20214161 | 20080494 | 1.55 | 92 | Palliative (P) | 2018-05-10 | 2018-05-15 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101339035 |
| 20214163 | 20080495 | 1.75 | 86.7 | null | 2019-04-14 | 2019-05-26 | LANREOTIDE | 02 | null | LANREOTIDE | 101639932 |
| 20214166 | 20080498 | null | 78.8 | null | 2017-06-21 | 2017-06-29 | HCX (Cape + Cisp + Tras) - Load | 02 | Y | TRIAL | 100353394 |
| 20214169 | 20080500 | null | 89 | null | 2018-08-21 | 2018-09-18 | HCX (Cape + Cisp + Tras) - Load | 02 | null | LANREOTIDE | 101598403 |
| 20214171 | 20080502 | 1.66 | 89 | Curative (C) | 2016-11-11 | 2016-11-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101072474 |
| 20214172 | 20080503 | 1.69 | 75.7 | Palliative (P) | 2021-09-11 | 2021-09-21 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100282417 |
| 20214173 | 20080504 | 1.58 | 73.6 | Palliative (P) | 2019-04-09 | 2019-04-17 | GO2 TRIAL | N | N | TRIAL | 101137504 |
| 20214174 | 20080505 | 1.78 | 83.8 | Curative (C) | 2019-08-22 | 2019-09-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100590873 |
| 20214175 | 20080506 | 1.7 | 64.5 | Palliative (P) | 2017-04-20 | 2017-04-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101822188 |
| 20214177 | 20080508 | 1.71 | 89.6 | Neo-adjuvant (N) | 2019-07-05 | 2019-07-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101110349 |
| 20214178 | 20080509 | 1.75 | 85.5 | Curative (C) | 2017-03-24 | 2017-04-08 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101725707 |
| 20214180 | 20080511 | 1.62 | 69.2 | null | 2019-01-12 | 2019-01-12 | IMATINIB | 02 | null | IMATINIB | 100507114 |
| 20214181 | 20080512 | 1.7 | 67.5 | Palliative (P) | 2018-09-11 | 2018-09-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100562933 |
| 20214182 | 20080513 | null | null | Curative (C) | null | 2019-06-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101756387 |
| 20214183 | 20080514 | 1.75 | 64.9 | Curative (C) | 2018-08-24 | 2018-09-11 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100664284 |
| 20214184 | 20080515 | 1.8 | 61 | null | 2016-12-07 | 2016-12-07 | Imatinib 400mg | 02 | null | IMATINIB | 101524831 |
| 20214185 | 20080516 | 1.8 | 68.8 | Palliative (P) | 2018-03-15 | 2018-03-15 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101730883 |
| 20214186 | 20080517 | 1.85 | 76.8 | Curative (C) | 2019-02-02 | 2019-02-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100825243 |
| 20214187 | 20080518 | 1.71 | 56.2 | Curative (C) | 2016-11-12 | 2016-11-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100475628 |
| 20214188 | 20080519 | 0 | 118.6 | Curative (C) | 2019-01-30 | 2019-01-30 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 101456881 |
| 20214191 | 20080521 | null | 90.4 | null | null | 2019-10-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 101210153 |
| 20214192 | 20080522 | 1.6 | 50.2 | Palliative (P) | 2018-11-16 | 2018-11-16 | Trial Unspecified | 1 | N | TRIAL | 100271636 |
| 20214193 | 20080523 | 1.75 | 69.8 | Palliative (P) | 2018-08-10 | 2018-08-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101363320 |
| 20214195 | 20080525 | 1.71 | 73.9 | Curative (C) | 2018-10-27 | 2018-11-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101043462 |
| 20214196 | 20080526 | 1.81 | 65.4 | Curative (C) | 2018-05-25 | 2018-06-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | N | FLUOROURACIL + MITOMYCIN + RT | 101641671 |
| 20214197 | 20080527 | 1.6 | 62.1 | Palliative (P) | 2018-01-14 | 2018-02-05 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100107624 |
| 20214198 | 20080528 | 1.78 | 66.5 | Curative (C) | 2016-05-31 | 2016-06-16 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101745448 |
| 20214199 | 20080529 | 1.58 | 90 | Palliative (P) | 2016-07-13 | 2016-07-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100534109 |